A monoclonal competitive radioimmunoassay (CompRIAm) which detects antibody to herpesvirus simiae (B virus) in monkey and human sera and antibody to SA8 virus in monkey sera but not antibody to herpes simplex virus in human sera is described. Of 232 serum samples from wild-caught cynomolgus monkeys, 117 serum samples were positive when tested by CompRIAm. The results were in close agreement (97.5%) with B virus neutralizing antibody results on the same sera. Sera from 97 wild-caught rhesus monkeys and 92 wild-caught baboons were also tested. Sera. The simian sera were collected from 232 wild-caught cynomolgus monkeys from Indonesia and the Philippines, 92 wild-caught Ethiopian baboons, and 97 wild-caught Chinese rhesus monkeys. These sera were submitted to the Virus Reference Division for antibody testing during 1990.
A monoclonal competitive radioimmunoassay (CompRIAm) which detects antibody to herpesvirus simiae (B virus) in monkey and human sera and antibody to SA8 virus in monkey sera but not antibody to herpes simplex virus in human sera is described. Of 232 serum samples from wild-caught cynomolgus monkeys, 117 serum samples were positive when tested by CompRIAm. The results were in close agreement (97.5%) with B virus neutralizing antibody results on the same sera. Sera from 97 wild-caught rhesus monkeys and 92 wild-caught baboons were also tested. The CompRIAm was able to differentiate between sera that had neutralizing antibody to B virus and SA8 virus and those that did not, although the discrimination was not as clear as that in the tests on cynomolgus monkey sera. Sequential sera from two humans with confirmed cases of B virus infection were tested by CompRIAm. B virus antibody was detected in sera from both humans. None of 237 other serum samples from blood donors and patients attending sexually transmitted disease clinics reacted in the CompRIAm.
Herpesvirus simiae (B virus) is an alpha herpesvirus of macaque monkeys. It is very closely related to herpes simplex virus (HSV) of humans. B virus infection in macaques is generally subclinical and resembles human HSV infection. There is a primary oral or genital infection followed by virus latency in the nerve ganglia. In humans, however, B virus can cause a devastating neurological illness. Of the 25 well-documented human B virus infections, an ascending encephalomyelitis was diagnosed in 22 patients, and in 16 of these (72%) patients the outcome was fatal (3, 6, 13) . Simian agent 8 (SA8) is a closely related alpha herpesvirus of baboons and African green monkeys. It has not been shown unequivocally to infect humans, but it may have been the cause of one fatal case of encephalitis (10) . The apparent success of early acyclovir therapy in controlling clinical illness caused by B virus in humans emphasizes the need for prompt and accurate laboratory diagnosis (6) .
B virus and HSV share growth characteristics and antigens, and it is difficult to distinguish by culture or serologically between B virus infection and HSV infection. Primary diagnosis of B virus infection is by isolation of the virus in cell culture. B virus identification has been described by indirect immunofluorescence with monoclonal antibodies (MAbs) (2) or by restriction enzyme digestion of viral DNA (12) . Isolation of virus is not always possible, however, and it is important to be able to diagnose B virus infection serologically. Several methods for detecting B virus antibody have been described: neutralization (7), a dot immunoassay (5) , and an enzyme-linked immunosorbent assay (ELISA) (8) Fig. 1 . The sera tested fell into two distinct groups, indicating good discrimination by the assay. The results were used to set a cutoff level for the assay. In previous tests for neutralizing antibody, 123 of the serum samples were shown to contain antibodies against B virus; 117 (95%) of them gave >45% inhibition by CompRIAm. The mean inhibition given by these 117 serum samples was 83.5% (standard deviation, ±9.25%). On the basis of these results, the positive cutoff value for CompRIAm was set at 56% inhibition (3 standard deviations below the mean). The remaining 109 serum samples, which were negative by neutralization, gave inhibitions in the CompRIAm of less than 35%. Their mean inhibition was 8.8% (standard deviation, ±6.9%). On this basis, a negative cutoff was set at 30% inhibition. Test sera giving inhibitions of between 30 and 56% were considered equivocal. By using these criteria, there was 95% agreement between CompRIAm and B virus neutralization. The six serum samples that gave discrepant results were collected from wild-caught cynomolgus monkeys from the Philippines and Indonesia. Five of these six serum samples had low serum neutralization titers (titer, 4) .
Reactivity of human sera in the CompRIAm. A total of 237 human serum samples were tested by CompRIAm. These sera were previously tested by polyclonal competitive radioimmunoassay, and 116 (49%) serum samples were shown to contain herpesvirus antibodies. None of the human sera tested reacted positively in the CompRIAm.
Reactivities of paired human sera showing rises in titer to VZV or HSV in the CompRiAm. Some 24 pairs of serum samples were tested in the CompRIAm. Of these, 10 showed rises in titer to VZV, 2 showed rises in titer to HSV, and 12 showed rises in titer to both VZV and HSV when tested in the complement fixation test. None of these acute-phase or convalescent-phase sera gave positive results when tested by CompRIAm.
Reactivities of sera and CSF from two humans with B virus infection in the CompRIAm. Sequential serum samples and a CSF sample from patient 1 were tested. He had an encephalomyelitic illness caused by B virus; he recovered from the illness (1). Serum from another patient (patient 2) was tested; the patient recovered from the illness (4). The results are presented in Table 1 . Significant reactivity was detected in the CompRIAm in sera collected from both patients and in the CSF of patient 1. Reactivities of rhesus monkey sera in the CompRLAm. A total of 97 rhesus monkey serum samples were tested by CompRIAm. The distribution of reactivities of these sera is shown in Fig. 2 indicating discrimination between B virus antibody-positive and -negative sera. There was 85% agreement between neutralization and CompRIAm on rhesus monkey sera.
Reactivities of baboon sera in the CompRIAm. A total of 92 baboon serum samples were tested by CompRIAm. The sera Studies are under way to establish whether it can be used to examine sera from workers who are in regular contact with monkeys to look for the possibility of B virus latency in humans.
